CME/NCPD Credit Available

Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer With Anne Chiang, MD, PhD, and Henry Park, MD, MPH

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usuall...

New Opportunities for Improved Patient Outcomes in Graft-Versus-Host Disease With Shernan Holtan, MD, and Carrie Kitko, MD

Keira Smith

Expert Analysis

Oncology Data Advisor™ · New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 1...

New Clinical Perspectives in the Management of Marginal Zone Lymphoma With Ariela Noy, MD, and Matthew Matasar, MD

Keira Smith

Expert Analysis

i3 Health · New Perspectives in the Management of Marginal Zone Lymphoma Marginal zone lymphoma (MZL) comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs) (Cerhan & Haberman, 2021). According to the World Health Organization classification, there are three subtypes: extranodal MZL, also referred to as mucosa-associated l...

Diagnosis and Evidence-Based Management of T-Cell Lymphoma With Aaron Goodman, MD

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Diagnosis and Evidence-Based Management of T-Cell Lymphoma T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival ...

Treatment Advances in Waldenstrom Macroglobulinemia With Morie Gertz, MD, MACP

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Treatment Advances in Waldenstrom Macroglobulinemia Waldenstrom macroglobulinemia (WM) is a rare cancer of B lymphocytes associated with lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM) (LLS, 2021). Often considered a disease oc...

Updates in Mantle Cell Lymphoma With John Leonard, MD

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Updates in Mantle Cell Lymphoma Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin lymphoma that comprises approximately 5% of all lymphomas. Compared with patients who have other aggressive lymphomas, patients with MCL often do not respond as well to treatment (ACS, 2...

Updates in Myelodysplastic Syndromes: Improving Patient Outcomes With Mikkael Sekeres, MD

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Updates in Myelodysplastic Syndromes: Improving Patient Outcomes Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid malignancies that derive from abnormal multipotent progenitor cells and are characterized by bone marrow failure and peripheral blood cytopenias (NCCN, 2021; Garci...

Improving Outcomes in Hodgkin Lymphoma With Louis Diehl, MD

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Improving Outcomes in Hodgkin Lymphoma Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed each year in the United States (Siegel et al, 2021). While the advent of novel therapies is leading to significantly improved outcomes, HL treatment con...

Therapy of B-Cell Acute Lymphoblastic Leukemia, An Evolving Landscape: Amir Fathi, MD

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the proliferation of immature lymphoid cells throughout the bone marrow and blood (Ranathunga et al, 2020). Although survival has improved in recent years due to ...

Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer With Ritu Salani, MD, MBA, and Floor J. Backes, MD

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer Cancer of the uterine corpus, also called endometrial cancer (EC), is the most common cancer of the female genital tract, with an estimated 65,950 new cases diagnosed and 12,550 deaths annually in the United States (ACS, 2022)....

New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia With Gary Lyman, MD, MPH, and Maura Abbott, PhD, AOCNP®, CPNP

Keira Smith

Expert Analysis

Oncology Data Advisor™ · New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia Chemotherapy-induced neutropenia (CIN) is a potentially life-threatening toxicity of chemotherapy that has been recognized as a major risk factor for the development of infections in patients with cancer (NCCN, 2021). The severity and du...

Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer With Ticiana Leal, MD, and Beth Sandy, MSN, CRNP

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 84% of cases are classified as non–small cell lung cancer (NSCLC) (ACS, 2022). Th...

Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer With Mark Kris, MD, and Victoria Sherry, DNP, CRNP, AOCNP®

Keira Smith

Expert Analysis

Oncology Data Advisor™ · Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer Squamous cell lung carcinoma is a distinct histologic subtype of non–small cell lung cancer (NSCLC) that accounts for approximately 25% to 30% of all NSCLC cases and is associated with approximately 30% shorter survival compared with other ...

Optimizing Treatment and Functional Outcomes in Head and Neck Squamous Cell Carcinoma With Barbara Burtness, MD, and Lynsey Teulings, NP

Keira Smith

Podcast

· Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,630 new cases are diagnosed in the United States annually, and 14,620 people die of the disease (Siegel et al, 2021). Historically, HNSCC has been ...

Novel and Emerging Treatment Strategies for Advanced Classical Hodgkin Lymphoma With Kami Maddocks, MD, and Kelly Brassil, PhD, RN, FAAN

Keira Smith

Podcast

Hodgkin lymphoma is a rare malignancy involving the lymph nodes and lymphatic system, with 8,830 new cases diagnosed and accounting for 960 deaths each year in the United States (Siegel et al, 2021). In contrast with other cancers whose risk increases with age, the risk for HL increases in patients between 15 and 30 years of age, decreases during m...

Advances in the Treatment of Relapsed/Refractory Immune Thrombocytopenia With Keith McCrae, MD, and Phyllis McKiernan, APN, MSN, OCN®

Keira Smith

Podcast

Immune thrombocytopenia is an acquired immune-mediated disorder defined as a peripheral blood platelet count <100 x109/L with no known cause (Rodeghiero et al, 2009). The incidence is estimated to be 1.6 to 3.9 per 100,000 patient-years in adults and 0.46 to 12.5 per 100,000 patient-years in children (Terrell et al, 2010). Research has shown tha...

New Perspectives on Diagnosis and Treatment of EGFR Exon 20 Insertion–Mutant NSCLC With Helena Yu, MD, and Maria Arcila, MD

Keira Smith

Podcast

An estimated 235,760 new cases of lung cancer are reported in the United States annually, and 131,880 people die of the disease. Approximately 84% of cases are classified as non-small cell lung cancer (NSCLC) (ACS, 2021). The most frequent genomic aberration among patients with NSCLC is the epidermal growth factor receptor (EGFR) mutation, approxim...

New Opportunities in Advanced KRAS Mutation–Positive NSCLC With D. Ross Camidge, MD, PhD, and Beth Sandy, MSN, CRNP, OCN®

Sarah Williams, MAT

Podcast

An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 84% of cases are classified as non-small cell. Most patients are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management (ACS, 2020). Although 7...

Burnout: Prevention and Coping Tactics for Oncologists With Daniel McFarland, DO

Sarah Williams, MAT

Podcast

Physician burnout and work-related stress are serious and prevalent issues in oncology, with nearly 45% of oncologists experiencing signs of burnout. Recently, this problem has been further exacerbated by the challenges brought about by the COVID-19 pandemic. In this episode of Oncology Data Advisor, Daniel McFarland, DO, a head and neck medical on...

Update on Immunotherapeutic Strategies for Advanced Merkel Cell Carcinoma With Shailender Bhatia, MD and Ciara Kelly, MBBCh, BAO

Sarah Williams, MAT

Podcast

Merkel cell carcinoma is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 2,488 cases are diagnosed in the United States annually (Paulson et al, 2018). The incidence of MCC has risen rapidly during the past few decades, which has been attributed in part t...

About

Resources

Subscribe

Follow Us